Candidate varicella vaccine

Phase 3Vaccine

GSK

Candidate varicella vaccine is one of 39 biologic programs targeting Chickenpox. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ChickenpoxActive, not recruiting

MalariaActive, not recruiting

ChickenpoxPhase 3

Active, not recruiting

MalariaPhase 3

Active, not recruiting

Competition

Competitive Landscape

479 competitors in Malaria

#DrugCompanyPhaseTrials

Candidate varicella vaccine

GSK

Phase 3

1 2

Biltricide

Bayer

Preclinical

1 3

Stelara

Johnson & Johnson

Preclinical

—4

Hydroxychloroquine Sulfate

Novartis

Preclinical

—5

Iron

WWatson Pharmaceuticals

Preclinical

1 6

IV LBH589

Novartis

Preclinical

1 7

Mefloquine Plus Artesunate

Medicines for Malaria Venture

Preclinical

1 8

IV Ceftriaxone

RRESnTEC, Institute of Research

Preclinical

1 9

RTS,S/AS01E

GSK

Preclinical

4 10

Piperaquine

UUniversity of Oxford

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Recruiting

Chickenpox

NCT06855160

Clinical

Trials by Indication[1]

Chickenpox1 trial

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age

Recruiting· GSK logo

GSK·Phase 3·NCT06855160·900 enrolled

Malaria1 trial

Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine.

Completed· GSK logo

GSK·Phase 3·NCT02699099·699 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Candidate varicella vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Candidate varicella vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Candidate varicella vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 3[1]
Company: GSK

Candidate varicella vaccine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Chickenpox1 trial

Malaria1 trial

References

Drug Info

Quick Facts

Related News